Marco Ladetto

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/6359331/marco-ladetto-publications-by-year.pdf
Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

284 papers	8,528 citations	53 h-index	88 g-index
292 ext. papers	9,860 ext. citations	3.7 avg, IF	5.32 L-index

#	Paper	IF	Citations
284	Patterns of neutralizing humoral response to SARS-CoV-2 infection among hematologic malignancy patients reveal a robust immune response in anti-cancer therapy-naive patients.. *Blood Cancer Journal*, **2022**, 12, 8	7	1
283	Rituximab, Bendamustine and Cytarabine Followed By Venetoclax (V-RBAC) in High-Risk Elderly Patients with Mantle Cell Lymphoma. *Blood*, **2021**, 138, 2427-2427	2.2	1
282	A Comprehensive and Systematic Analysis of Minimal Residual Disease (MRD) Monitoring in Follicular Lymphoma: Results from the Fondazione Italiana Linfomi (FIL) FOLL12 Trial. *Blood*, **2021**, 138, 41-41	2.2	
281	Impact of Immunochemotherapy with R-Bendamustine or R-CHOP in the Post-Induction Management of Treatment Naïve Advanced Stage Follicular Lymphoma Patients: A Subset Analysis of the FOLL12 Trial By the Fondazione Italiana Linfomi (FIL). *Blood*, **2021**, 138, 811-811	2.2	1
280	A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study. *Blood Advances*, **2021**,	7.8	4
279	Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 Study. *Journal of Clinical Oncology*, **2021**, JCO2101234	2.2	7
278	Outcomes of older patients with follicular lymphoma using individual data from 5922 patients in 18 randomized controlled trials. *Blood Advances*, **2021**, 5, 1737-1745	7.8	0
277	Targeted locus amplification to detect molecular markers in mantle cell and follicular lymphoma. *Hematological Oncology*, **2021**, 39, 293-303	1.3	4
276	Outcomes following second allogeneic haematopoietic cell transplantation in patients with myelofibrosis: a retrospective study of the Chronic Malignancies Working Party of EBMT. *Bone Marrow Transplantation*, **2021**, 56, 1944-1952	4.4	1
275	Application of the Euro Clonality next-generation sequencing-based marker screening approach to detect immunoglobulin heavy chain rearrangements in mantle cell lymphoma patients: first data from the Fondazione Italiana Linfomi MCL0208 trial. *British Journal of Haematology*, **2021**, 194, 378-381	4.5	0
274	A Phase III study of zanubrutinib plus rituximab versus bendamustine plus rituximab in transplant-ineligible, untreated mantle cell lymphoma. *Future Oncology*, **2021**, 17, 255-262	3.6	5
273	Total body irradiation + fludarabine compared to busulfan + fludarabine as "reduced-toxicity conditioning" for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acute Leukemia Working Party of the EBMT. *Bone Marrow Transplantation*, **2021**, 56, 481-491	4.4	0
272	Minimal Residual Disease (MRD) in Indolent Lymphomas. *Hematologic Malignancies*, **2021**, 21-39	0	
271	A brief rituximab, bendamustine, mitoxantrone (R-BM) induction followed by rituximab consolidation in elderly patients with advanced follicular lymphoma: a phase II study by the Fondazione Italiana Linfomi (FIL). *British Journal of Haematology*, **2021**, 193, 280-289	4.5	3
270	Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trial. *Lancet Haematology,the*, **2021**, 8, e34-e44	14.6	9
269	Upfront intensive chemo-immunotherapy with autograft in 199 adult mantle cell lymphoma patients: prolonged survival and cure potentiality at long term. *Bone Marrow Transplantation*, **2021**, 56, 2606-2609	4.4	1
268	COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies. *British Journal of Haematology*, **2021**, 195, 371-377	4.5	15

267	Quality Assessment for PCR-based Minimal Residual Disease in Lymphoma: 10 Years of Cross-laboratory Standardization Process Within the Fondazione Italiana Linfomi MRD Network. *HemaSphere*, **2021**, 5, e639	0.3	
266	The role of autologous haematopoietic stem-cell transplantation in mantle cell lymphoma. *Lancet Haematology,the*, **2021**, 8, e617-e619	14.6	
265	Spontaneous splenic rupture during induction therapy in acute myeloid leukemia: An unusual case. *Radiology Case Reports*, **2021**, 16, 3406-3409	1	0
264	Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma in the Era of New Drugs and CAR-T Cell Therapy. *Cancers*, **2021**, 13,	6.6	5
263	A Clinical Prognostic Model Based on Machine Learning from the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III Trial.. *Cancers*, **2021**, 14,	6.6	1
262	Controversies in the Treatment of Follicular Lymphoma. *HemaSphere*, **2020**, 4, e317	0.3	9
261	Droplet Digital PCR Assay for : Clinical Applications in Waldenstrm Macroglobulinemia. *HemaSphere*, **2020**, 4, e324	0.3	3
260	Pharmacogenomics Drives Lenalidomide Efficacy and MRD Kinetics in Mantle Cell Lymphoma after Autologous Transplantation: Results from the MCL0208 Multicenter, Phase III, Randomized Clinical Trial from the Fondazione Italiana Linfomi (FIL). *Blood*, **2020**, 136, 16-17	2.2	0
259	Daratumumab after Allogeneic Hematopoietic Stem Cell Transplantation in Multiple Myeloma: Safety and Efficacy. a Retrospective Study from the Cmwp EBMT. *Blood*, **2020**, 136, 26-27	2.2	
258	Minimal Residual Disease-Driven Treatment Intensification By Sequential Addition of Ibrutinib to Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: Results of the Monotherapy and Combination Phases of the Improve Study. *Blood*, **2020**, 136, 21-22	2.2	2
257	Droplet Digital PCR Quantification of Mantle Cell Lymphoma Follow-up Samples From Four Prospective Trials of the European MCL Network. *HemaSphere*, **2020**, 4, e347	0.3	19
256	Organizational determinants of hospital stay: establishing the basis of a widespread action on more efficient pathways in medical units. *Internal and Emergency Medicine*, **2020**, 15, 1011-1019	3.7	3
255	Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Annals of Oncology*, **2020**, 31, 17-29	10.3	77
254	Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. *Lancet Haematology,the*, **2020**, 7, e737-e745	14.6	223
253	Minimal Residual Disease in Mantle Cell Lymphoma: Methods and Clinical Significance. *Hematology/Oncology Clinics of North America*, **2020**, 34, 887-901	3.1	3
252	Immunoglobulin kappa deleting element rearrangements are candidate targets for minimal residual disease evaluation in mantle cell lymphoma. *Hematological Oncology*, **2020**, 38, 698-704	1.3	1
251	mutations and disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study. *Haematologica*, **2020**, 105, 1604-1612	6.6	52
250	Incidence and outcome of Kaposi sarcoma after hematopoietic stem cell transplantation: a retrospective analysis and a review of the literature, on behalf of infectious diseases working party of EBMT. *Bone Marrow Transplantation*, **2020**, 55, 110-116	4.4	8

249	Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes: EBMT Registry Analyses Following Allogeneic Stem Cell Transplantation for B-Cell Malignancies. *Frontiers in Immunology*, **2020**, 11, 613954	8.4	1
248	Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the prospective, multicenter randomized GITMO-IIL trial. *Haematologica*, **2019**, 104, 2241-2248	6.6	6
247	A B-cell receptor-related gene signature predicts response to ibrutinib treatment in mantle cell lymphoma cell lines. *Haematologica*, **2019**, 104, e410-e414	6.6	2
246	Methods and role of minimal residual disease after stem cell transplantation. *Bone Marrow Transplantation*, **2019**, 54, 681-690	4.4	3
245	Minimal residual disease (MRD) in non-Hodgkin lymphomas: Interlaboratory reproducibility on marrow samples with very low levels of disease within the FIL (Fondazione Italiana Linfomi) MRD Network. *Hematological Oncology*, **2019**, 37, 368-374	1.3	7
244	Bleomycin, vinblastine and dacarbazine combined with nonpegylated liposomal doxorubicin (MBVD) in elderly (≥70 years) or cardiopathic patients with Hodgkin lymphoma: a phase-II study from Fondazione Italiana Linfomi (FIL). *Leukemia and Lymphoma*, **2019**, 60, 2890-2898	1.9	5
243	Definition and Validation of the New Elderly Prognostic Index (EPI) for Elderly Patients with Diffuse Large B-Cell Lymphoma Integrating Geriatric and Clinical Assessment: Results of the Prospective "Elderly Project" on 1353 Patients By the Fondazione Italiana Linfomi. *Blood*, **2019**, 134, 398-398	2.2	5
242	EARLY STAGE Follicular Lymphoma: First Results of the FIL "Miro" Study, a Multicenter Phase II Trial Combining Local Radiotherapy and MRD-Driven Immunotherapy. *Blood*, **2019**, 134, 124-124	2.2	4
241	Outcomes Following Second Allogenic Haematopoietic Cell Transplantation in Patients with Myelofibrosis: A Retrospective Study on Behalf of the Chronic Malignancies Working Party of EBMT. *Blood*, **2019**, 134, 698-698	2.2	1
240	Triangle: Autologous Transplantation after a Rituximab/Ibrutinib/ara-c Containing Induction in Generalized Mantle Cell Lymphoma - a Randomized European MCL Network Trial. *Blood*, **2019**, 134, 2816-2816	2.2	7
239	A Multistate Survival Analysis for Patients with Follicular Lymphoma (FL) Using 13 First-Line Randomized Trials from FL Analysis of Surrogate Hypothesis (FLASH) Group. *Blood*, **2019**, 134, 2812-2812	2.2	
238	Applying Data Warehousing to a Phase III Clinical Trial From the Fondazione Italiana Linfomi Ensures Superior Data Quality and Improved Assessment of Clinical Outcomes. *JCO Clinical Cancer Informatics*, **2019**, 3, 1-15	5.2	5
237	A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the Fondazione Italiana Linfomi MCL-0208 trial. *Haematologica*, **2018**, 103, 849-856	6.6	12
236	ESMO Consensus Conference on malignant lymphoma: general perspectives and recommendations for the clinical management of the elderly patient with malignant lymphoma. *Annals of Oncology*, **2018**, 29, 544-562	10.3	42
235	Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi. *Leukemia and Lymphoma*, **2018**, 59, 2904-2910	1.9	5
234	Minimal Residual Disease in Multiple Myeloma. *Hematologic Malignancies*, **2018**, 97-109	0	1
233	Outcome of a Salvage Third Autologous Stem Cell Transplantation in Multiple Myeloma. *Biology of Blood and Marrow Transplantation*, **2018**, 24, 1372-1378	4.7	17
232	Droplet Digital PCR for Minimal Residual Disease Detection in Mature Lymphoproliferative Disorders. *Methods in Molecular Biology*, **2018**, 1768, 229-256	1.4	12

231	Highly sensitive mutation detection by droplet digital polymerase chain reaction in Waldenström macroglobulinemia. *Haematologica*, **2018**, 103, 1029-1037	6.6	32
230	Progressive telomere shortening is part of the natural history of chronic lymphocytic leukaemia and impacts clinical outcome: evidences from long term follow-up. *British Journal of Haematology*, **2018**, 181, 693-695	4.5	1
229	Ficoll-hypaque separation vs whole blood lysis: Comparison of efficiency and impact on minimal residual disease analysis. *International Journal of Laboratory Hematology*, **2018**, 40, 201-208	2.5	6
228	Lenalidomide Maintenance after Autologous Transplantation Prolongs PFS in Young MCL Patients: Results of the Randomized Phase III MCL 0208 Trial from Fondazione Italiana Linfomi (FIL). *Blood*, **2018**, 132, 401-401	2.2	6
227	Comprehensive Minimal Residual Disease (MRD) Analysis of the Fondazione Italiana Linfomi (FIL) MCL0208 Clinical Trial for Younger Patients with Mantle Cell Lymphoma: A Kinetic Model Ensures a More Refined Risk Stratification. *Blood*, **2018**, 132, 920-920	2.2	7
226	Molecular Subtypes of Splenic Marginal Zone Lymphoma (SMZL) Are Associated with Distinct Pathogenic Mechanisms and Outcomes - Interim Analysis of the IELSG46 Study. *Blood*, **2018**, 132, 922-922	2.2	2
225	The Engineered MIPI (e-MIPI), a Candidate Data-Mining Based Mantle Cell Lymphoma Prognostic Index Developed from the Dataset of the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III Trial. *Blood*, **2018**, 132, 2890-2890	2.2	
224	Minimal Residual Disease in Indolent Lymphomas: A Critical Assessment. *Current Treatment Options in Oncology*, **2018**, 19, 71	5.4	5
223	Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Annals of Oncology*, **2018**, 29, iv30-iv40	10.3	99
222	STAble: a novel approach to de novo assembly of RNA-seq data and its application in a metabolic model network based metatranscriptomic workflow. *BMC Bioinformatics*, **2018**, 19, 184	3.6	1
221	Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Annals of Oncology*, **2018**, 29, iv19-iv29	10.3	142
220	Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: a phase II clinical trial of the Fondazione Italiana Linfomi. *Haematologica*, **2017**, 102, e203-e206	6.6	17
219	Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized Trials. *Journal of Clinical Oncology*, **2017**, 35, 552-560	2.2	69
218	Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi. *Lancet Haematology,the*, **2017**, 4, e15-e23	14.6	75
217	Data quality improvement of a multicenter clinical trial dataset. *Annual International Conference of the IEEE Engineering in Medicine and Biology Society IEEE Engineering in Medicine and Biology Society Annual International Conference*, **2017**, 2017, 1190-1193	0.9	5
216	HashClone: a new tool to quantify the minimal residual disease in B-cell lymphoma from deep sequencing data. *BMC Bioinformatics*, **2017**, 18, 516	3.6	7
215	Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Annals of Oncology*, **2017**, 28, iv62-iv71	10.3	134
214	Khorana score and histotype predicts incidence of early venous thromboembolism in non-Hodgkin lymphomas. A pooled-data analysis of 12 clinical trials of Fondazione Italiana Linfomi (FIL). *Thrombosis and Haemostasis*, **2017**, 117,	7	19

213	Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myeloma. *Leukemia*, **2016**, 30, 1211-4	10.7	30
212	Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Annals of Oncology*, **2016**, 27, v83-v90	10.3	142
211	A Single-Center Pilot Prospective Study of Topical Application of Platelet-Derived Eye Drops for Patients with Ocular Chronic Graft-versus-Host Disease. *Biology of Blood and Marrow Transplantation*, **2016**, 22, 1664-1670	4.7	9
210	Comparison of different DNA extraction methods from peripheral blood cells: advice from the Fondazione Italiana Linfomi Minimal Residual Disease Network. *Leukemia and Lymphoma*, **2016**, 57, 400-410	10	3
209	Addition of Rituximab to Involved-Field Radiation Therapy Prolongs Progression-free Survival in Stage I-II Follicular Lymphoma: Results of a Multicenter Study. *International Journal of Radiation Oncology Biology Physics*, **2016**, 94, 783-91	4	30
208	Stem cell transplantation in multiple myeloma and other plasma cell disorders (report from an EBMT preceptorship meeting). *Leukemia and Lymphoma*, **2016**, 57, 1256-68	1.9	6
207	Outcomes for Elderly Patients (pts) with Follicular Lymphoma (FL) Using Individual Patient Data (IPD) from 5922 Pts in 18 Randomized Controlled Trials (RCTs): a Follicular Lymphoma Analysis of Surrogate Hypothesis (FLASH) Group Study. *Blood*, **2016**, 128, 1102-1102	2.2	2
206	Final Results of Northern Italy Leukemia Group (NILG) Trial 10/07 Combining Pediatric-Type Therapy with Minimal Residual Disease Study and Risk-Oriented Hematopoietic Cell Transplantation in Adult Acute Lymphoblastic Leukemia (ALL). *Blood*, **2016**, 128, 176-176	2.2	17
205	Distinct Immunogenetic Signatures in IgA Versus IgG Multiple Myeloma. *Blood*, **2016**, 128, 2062-2062	2.2	3
204	Rituximab, Bendamustine and Cytarabine (RBAC500) As Induction Therapy in Elderly Patients with Mantle Cell Lymphoma: Final Results of a Phase 2 Study from the Fondazione Italiana Linfomi. *Blood*, **2016**, 128, 472-472	2.2	2
203	Prognostic Impact of p190 and p210 Co-Expression in Early Molecular Response in Chronic Myeloid Leukemia (CML) Patients Treated with Tyrosin Kinase Inibitors. *Blood*, **2016**, 128, 5446-5446	2.2	1
202	Graft Purity and Composition Significantly Impact the Engraftment of Autologous Stem Cell Transplants. *Blood*, **2016**, 128, 5733-5733	2.2	1
201	"Osteonecrosis of Jaw (ONJ) after Bisphosphonate Treatment in Patients with Multiple Myeloma (MM) : Monocentric Experience of Decreasing ONJ Incidence after Preventive Measures.". *Blood*, **2016**, 128, 5917-5917	2.2	
200	Identification of DNA Copy Number Variations Associated with the Clinical Outcome in Young Mantle Cell Lymphoma Patients Treated with Cytarabine-Based High Dose Sequential Chemotherapy and Autologous Stem Cell Transplantation in the Prospective from the MCL0208 Phase III Trial from Fondazione Italiana Linfomi (FIL). *Blood*, **2016**, 128, 4099-4099	2.2	
199	Extranodal diffuse large B-cell lymphoma (DLBCL) and primary mediastinal B-cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Annals of Oncology*, **2016**, 27, v91-v102	10.3	69
198	Combinatorial targeting of nuclear export and translation of RNA inhibits aggressive B-cell lymphomas. *Blood*, **2016**, 127, 858-68	2.2	54
197	Randomized Trial Comparing R-CHOP Versus High-Dose Sequential Chemotherapy in High-Risk Patients With Diffuse Large B-Cell Lymphomas. *Journal of Clinical Oncology*, **2016**, 34, 4015-4022	2.2	49
196	Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survival. *Leukemia*, **2015**, 29, 689-95	10.7	68

195	Epigenomic evolution in diffuse large B-cell lymphomas. *Nature Communications*, **2015**, 6, 6921	17.4	81
194	Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Annals of Oncology*, **2015**, 26 Suppl 5, v116-25	10.3	397
193	Peripheral T-cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Annals of Oncology*, **2015**, 26 Suppl 5, v108-15	10.3	107
192	Minimal Residual Disease Detection by Droplet Digital PCR in Multiple Myeloma, Mantle Cell Lymphoma, and Follicular Lymphoma: A Comparison with Real-Time PCR. *Journal of Molecular Diagnostics*, **2015**, 17, 652-60	5.1	92
191	Autologous stem cell transplantation with in vivo purged progenitor cells shows long-term efficacy in relapsed/refractory follicular lymphoma. *American Journal of Hematology*, **2015**, 90, 230-4	7.1	8
190	Library Preparation Is the Major Factor Affecting Differences in Results of Immunoglobulin Gene Rearrangements Detection on Two Major Next-Generation Sequencing Platforms. *Blood*, **2015**, 126, 1411-1411	2.2	1
189	A Molecular Model for the Prediction of Progression Free Survival in Young Mantle Cell Lymphoma Patients Treated with Cytarabine-Based High Dose Sequential Chemotherapy and Autologous Stem Cell Transplantation: Results from the MCL0208 Phase III Trial from Fondazione Italiana Linfomi (FIL). *Blood*, **2015**, 126, 336-336	2.2	9
188	Simvastatin and downstream inhibitors circumvent constitutive and stromal cell-induced resistance to doxorubicin in IGHV unmutated CLL cells. *Oncotarget*, **2015**, 6, 29833-46	3.3	25
187	Highly Sensitive Droplet Digital PCR for MYD88L265P Mutation Detection and Minimal Residual Disease Monitoring in Waldenström Macroglobulinemia. *Blood*, **2015**, 126, 2645-2645	2.2	
186	Phase II Study of the Fondazione Italiana Linfomi on Gemcitabine Plus Romidepsin (GEMRO Regimen) in Relapsed and Refractory Peripheral T-Cell Lymphoma Patients. *Blood*, **2015**, 126, 3937-3937	2.2	
185	The Prognostic Role of Cell of Origin Profile and Myc Expression Assessed By Immunohistochemistry in Young High-Risk Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Results of First-Line Randomized BIO-DLCL04 Trial of Fondazione Italiana Linfomi (FIL). *Blood*, **2015**, 126, 5041-5041	2.2	
184	Khorana Score and Histotype Predict the Incidence of Early Venous Thromboembolism (VTE) in Non Hodgkin Lymphoma (NHL). a Pooled Data Analysis of Twelve Clinical Trials of Fondazione Italiana Linfomi (FIL). *Blood*, **2015**, 126, 3934-3934	2.2	
183	LONG-TERM Outcome of a Fondazione Italiana Linfomi Study Comparing Short Rituximab Maintenance Vs Observation after Brief First-LINE R-FND Chemoimmunotherapy Followed By Rituximab Consolidation in Elderly Patients with Advanced Follicular Lymphoma (FL). *Blood*, **2015**, 126, 3985-3985	2.2	
182	Identification of a Novel Gene Expression Signature in Mantle Cell Lymphoma from the Fondazione Italiana Linfomi (FIL)-MCL-0208 Trial: A Focus on the B Cell Receptor Pathway. *Blood*, **2015**, 126, 701-701	2.2	
181	MET dysregulation is a hallmark of aggressive disease in multiple myeloma patients. *British Journal of Haematology*, **2014**, 164, 841-50	4.5	18
180	Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders. *Leukemia*, **2014**, 28, 1299-307	10.7	213
179	Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Annals of Oncology*, **2014**, 25 Suppl 3, iii76-82	10.3	67
178	Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Annals of Oncology*, **2014**, 25 Suppl 3, iii70-5	10.3	127

177	Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi. *Annals of Oncology*, **2014**, 25, 1404-1410	10.3	114
176	Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial. *Lancet Oncology, The*, **2014**, 15, 730-7	21.7	135
175	High XBP1 expression is a marker of better outcome in multiple myeloma patients treated with bortezomib. *Haematologica*, **2014**, 99, e14-6	6.6	33
174	Inter- and intratumoral heterogeneity of BCL2 correlates with IgH expression and prognosis in follicular lymphoma. *Blood Cancer Journal*, **2014**, 4, e249	7	9
173	Comparison of two real-time quantitative polymerase chain reaction strategies for minimal residual disease evaluation in lymphoproliferative disorders: correlation between immunoglobulin gene mutation load and real-time quantitative polymerase chain reaction performance. *Hematological Oncology*, **2014**, 32, 133-8	1.3	10
172	Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: the FIL FOLL05 trial. *Clinical Cancer Research*, **2014**, 20, 6398-405	12.9	69
171	Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Annals of Oncology*, **2014**, 25 Suppl 3, iii83-92	10.3	104
170	The Prognostic Value of MYC, BCL2 and BCL6 Overexpression Evaluated By Immunohistochemistry (IHC) in De-Novo Diffuse Large B Cell Lymphoma (DLBCL) Treated with Rituximab-CHOP. *Blood*, **2014**, 124, 2964-2964	2.2	2
169	Prospective Molecular Monitoring of Minimal Residual Disease after Non-Myeloablative Allografting in Newly Diagnosed Multiple Myeloma. *Blood*, **2014**, 124, 44-44	2.2	1
168	Prognostic Impact of p190 and p210 Co-Expression at Diagnosis in Chronic Myeloid Leukemia (CML) Patients Treated with Imatinib. *Blood*, **2014**, 124, 5528-5528	2.2	3
167	Long-term results of the phase III GITMO/FIL trial of CHOP-R versus R-HDS plus autograft in high-risk follicular lymphoma (FL) at diagnosis.. *Journal of Clinical Oncology*, **2014**, 32, 8531-8531	2.2	
166	Efficacy of Reduced-Intensity Allogeneic Stem Cell Transplant after Brentuximab Vedotin in Patients with Hodgkin Lymphoma Relapsed after Autologous Transplant. *Blood*, **2014**, 124, 5943-5943	2.2	
165	Rituximab-based pre-emptive treatment of molecular relapse in follicular and mantle cell lymphoma. *Annals of Hematology*, **2013**, 92, 1503-11	3	13
164	Large genomic aberrations detected by SNP array are independent prognosticators of a shorter time to first treatment in chronic lymphocytic leukemia patients with normal FISH. *Annals of Oncology*, **2013**, 24, 1378-84	10.3	13
163	ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. *Annals of Oncology*, **2013**, 24, 857-77	10.3	225
162	Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome. *Blood*, **2013**, 122, 2673-82	2.2	154
161	ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). *Annals of Oncology*, **2013**, 24, 561-76	10.3	162
160	Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: a phase III randomized study by the Fondazione Italiana Linfomi. *Journal of Clinical Oncology*, **2013**, 31, 3351-9	2.2	48

159	MGA, a suppressor of MYC, is recurrently inactivated in high risk chronic lymphocytic leukemia. *Leukemia and Lymphoma*, **2013**, 54, 1087-90	1.9	57
158	Gastric marginal zone lymphoma of MALT type: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Annals of Oncology*, **2013**, 24 Suppl 6, vi144-8	10.3	132
157	Clinical implications and prognostic role of minimal residual disease detection in follicular lymphoma. *Therapeutic Advances in Hematology*, **2013**, 4, 189-98	5.7	12
156	Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Annals of Oncology*, **2013**, 24 Suppl 6, vi149-54	10.3	98
155	The lymphocyte to monocyte ratio improves the IPI-risk definition of diffuse large B-cell lymphoma when rituximab is added to chemotherapy. *American Journal of Hematology*, **2013**, 88, 1062-7	7.1	44
154	Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program. *Blood*, **2013**, 122, 3759-66	2.2	63
153	Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi. *Haematologica*, **2013**, 98, 1732-8	6.6	48
152	Inhibition Of Histone Deacetylases With Panobinostat As a Treatment For Relapsed Or Refractory Diffuse Large B-Cell Lymphoma: A Phase II Study By The Fondazione Italiana Linfomi. *Blood*, **2013**, 122, 3047-3047	2.2	2
151	Improved Igh-Based MRD Detection By Using Droplet Digital PCR: a Comparison With Real Time Quantitative PCR In MCL and MM. *Blood*, **2013**, 122, 4290-4290	2.2	1
150	A Comparative Analysis Of Next-Generation Sequencing and Real-Time Quantitative PCR For Minimal Residual Disease Detection In Follicular Lymphomas. *Blood*, **2013**, 122, 4293-4293	2.2	5
149	Radioimmunotherapy In Relapsed/Refractory Mantle Cell Lymphoma Patients: Final Results Of a European MCL Network Phase II Trial. *Blood*, **2013**, 122, 4384-4384	2.2	1
148	Prolonged Survival Of Poor Risk Follicular Lymphoma Patients Following Primary Treatment With Rituximab-Supplemented CHOP Or HDS With Autograft: Long-Term Results Of The Multicenter Randomized GITMO/FIL Trial. *Blood*, **2013**, 122, 551-551	2.2	3
147	Final Results Of Phase II Study Of Lenalidomide Plus Rituximab-CHOP21 In Elderly Untreated Diffuse Large B-Cell Lymphoma Focusing On The Analysis Of Cell Of Origin: REAL07 Trial Of The Fondazione Italiana Linfomi. *Blood*, **2013**, 122, 850-850	2.2	3
146	Long-Term Molecular Results Of The Gimema VEL-03-096 Trial: Molecular Remission Achievement and Loss Are Major Outcome Predictors. *Blood*, **2013**, 122, 2077-2077	2.2	
145	Next-Generation Sequencing and Real-Time Quantitative PCR For Quantification Of Low-Level Minimal Residual Disease In Acute Lymphoblastic Leukemia Of Adults. *Blood*, **2013**, 122, 351-351	2.2	
144	Relapsed Or Refractory Aggressive Non Hodgkin B-Cell Lymphomas Treated With Lenalidomide With/Without Rituximab Or Steroids: A Single Center Restrospective Study. *Blood*, **2013**, 122, 5119-5119	2.2	
143	Minimal Residual Disease Monitoring During Maintenance In Multiple Myeloma Patients. *Blood*, **2013**, 122, 3126-3126	2.2	1
142	Dysfunctional V9V2 T cells are negative prognosticators and markers of dysregulated mevalonate pathway activity in chronic lymphocytic leukemia cells. *Blood*, **2012**, 120, 3271-9	2.2	40

141	Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP. *Blood*, **2012**, 119, 2066-73	2.2	186
140	Telomere loss in Philadelphia-negative hematopoiesis after successful treatment of chronic myeloid leukemia: evidence for premature aging of the myeloid compartment. *Mechanisms of Ageing and Development*, **2012**, 133, 479-88	5.6	9
139	Syndecan-1 promotes the angiogenic phenotype of multiple myeloma endothelial cells. *Leukemia*, **2012**, 26, 1081-90	10.7	50
138	Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genes. *Haematologica*, **2012**, 97, 849-53	6.6	9
137	Del(13q14.3) length matters: an integrated analysis of genomic, fluorescence in situ hybridization and clinical data in 169 chronic lymphocytic leukaemia patients with 13q deletion alone or a normal karyotype. *Hematological Oncology*, **2012**, 30, 46-9	1.3	18
136	ALK Signaling and Target Therapy in Anaplastic Large Cell Lymphoma. *Frontiers in Oncology*, **2012**, 2, 41	5.3	33
135	Brief Chemoimmunotherapy Rituximab, Bendamustine, Mitoxantrone (R-BM) Followed by Rituximab Consolidation in Elderly Patients with Untreated Advanced Stage Follicular Lymphoma (FL): Preliminary Results of a Prospective Phase II Study by Fondazione Italiana Linfomi (FIL).. *Blood*, **2012**, 120, 2720-2720	2.2	1
134	Chemoimmunotherapy with R-CHOP or High Dose Sequential Therapy with Autologous Stem Cell Transplantation (R-HDS) for High Risk Diffuse Large B-Cell Lymphomas Patients: Results of the Randomized R-HDS0305 Trial by Gruppo Italiano Terapie Innovative Nei Linfomi (GITIL). *Blood*, **2012**	2.2	2
133	Next-Generation Sequencing and Real-Time Quantitative PCR for Minimal Residual Disease (MRD) Detection Using the Immunoglobulin Heavy Chain Variable Region: A Methodical Comparison in Acute Lymphoblastic Leukemia (ALL), Mantle Cell Lymphoma (MCL) and Multiple Myeloma (MM). *Blood*, **2012**, 120, 788-788	2.2	1
132	Rituximab-CHOP21 Plus Lenalidomide (LR-CHOP21) Is Effective and Feasible in Elderly Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results of Phase II REAL07 Study of the Fondazione Italiana Linfomi (FIL). *Blood*, **2012**, 120, 903-903	2.2	2
131	PCR-Based Minimal Residual Disease (MRD) Detection Is a Strong Independent Outcome Predictor Also in Rituximab-Intensive Non-ASCT-Based Programs: Results From the ML17638 Multicenter Randomised Phase III Trial for Elderly Follicular Lymphoma (FL) Patients of the Fondazione Italiana Linfomi (FIL). *Blood*, **2012**, 120, 787-787	2.2	
130	Large Genomic Aberrations Are Independent Prognosticators of A Shorter Time to First Treatment (TTT) in Chronic Lymphocytic Leukemia (CLL) Patients with A Normal FISH. *Blood*, **2012**, 120, 3906-3906	2.2	
129	The Mevalonate Pathway and Downstream Signal Transducers As Therapeutic Targets to Overcome Multidrug Resistance in Chronic Lymphocytic Leukemia (CLL). *Blood*, **2012**, 120, 3881-3881	2.2	
128	Identification of Novel Tumor-Associated Antigens in Chronic Lymphocytic Leukemia (CLL) by Serological Proteome Analysis (SERPA). *Blood*, **2012**, 120, 3878-3878	2.2	
127	The Peripheral Blood Lymphocyte to Monocyte Ratio At Diagnosis Is a Potent Outcome Predictor in Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Long-Term Analysis On 973 Patients Receiving Chemotherapy with or without Rituximab. *Blood*, **2012**, 120, 1553-1553	2.2	
126	Minimal Residual Disease Evaluated As Bcl2/Igh Rearrangement After Conventional Treatment Does Significantly Impact On Progression-Free Survival of Patients Affected by Follicular Lymphoma: The Experience of the Ancillary Trial Conducted by the Fondazione Italiana Linfomi (FIL). *Blood*, **2012**, 120, 3653-3653	2.2	
125	High Rates of Prolonged Molecular Remissions After Tandem Autologous-Nonmyeloablative Allografting in Newly Diagnosed Myeloma. *Blood*, **2012**, 120, 4204-4204	2.2	
124	IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells. *Leukemia*, **2011**, 25, 828-37	10.7	53

123	The host genetic background of DNA repair mechanisms is an independent predictor of survival in diffuse large B-cell lymphoma. *Blood*, **2011**, 117, 2405-13	2.2	28
122	Genome-wide DNA profiling better defines the prognosis of chronic lymphocytic leukaemia. *British Journal of Haematology*, **2011**, 154, 590-9	4.5	35
121	13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia. *Genes Chromosomes and Cancer*, **2011**, 50, 633-43	5	57
120	Minimal residual disease detection in lymphoma and multiple myeloma: impact on therapeutic paradigms. *Hematological Oncology*, **2011**, 29, 167-76	1.3	33
119	Brief Chemoimmunotherapy R-FND with Rituximab Consolidation Followed by Randomization Between Rituximab Maintenance Vs. Observation As First Line Treatment in Elderly Patients with Advanced Follicular Lymphoma (FL): Final Results of a Prospective Randomized Trial by Italian Lymphoma Foundation (FIL). *Blood*, **2011**, 118, 777-777	2.2	4
118	LONG-TERM RESULTS of the GIMEMA VTD Consolidation TRIAL In Autografted MULTIPLE Myeloma PATIENTS (VEL-03-096): IMPACT of Minimal RESIDUAL DISEASE Detection by REAL Time Quantitative PCR On LATE Recurrences and Overall SURVIVAL. *Blood*, **2011**, 118, 827-827	2.2	6
117	Progressive Telomere Shortening Is Part of the Natural History of Chronic Lymphocytic Leukemia (CLL) and Impacts Clinical Outcome. *Blood*, **2011**, 118, 2845-2845	2.2	
116	The Mevalonate Pathway As a Metabolic Target to Circumvent Multidrug-Resistance in Chronic Lymphocytic Leukemia Cells. *Blood*, **2011**, 118, 735-735	2.2	
115	SNP-Arrays Provide New Insights Into the Pathogenesis of Richter Syndrome (RS). *Blood*, **2011**, 118, 263-263	2.2	
114	AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition. *Oncogene*, **2010**, 29, 2325-36	9.2	90
113	Comparative assessment of telomere length before and after hematopoietic SCT: role of grafted cells in determining post-transplant telomere status. *Bone Marrow Transplantation*, **2010**, 45, 505-12	4.4	12
112	Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. *Journal of Clinical Oncology*, **2010**, 28, 2077-84	2.2	223
111	The adulthood of MRD detection in MCL. *Blood*, **2010**, 115, 3180-1	2.2	
110	Telomeres and telomerase in normal and malignant B-cells. *Hematological Oncology*, **2010**, 28, 157-67	1.3	10
109	Low CD49d expression and long telomere identify a chronic lymphocytic leukemia subset with highly favourable outcome. *American Journal of Hematology*, **2010**, 85, 619-22	7.1	9
108	Home management of hematological patients requiring hospital admission. *Archives of Gerontology and Geriatrics*, **2010**, 51, 309-11	4	4
107	The Outcome of Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Rituximab-CHOP (R-CHOP) Is Not Predicted by 18-FDG-Positron Emission Tomography/Computerized Tomography (PET) Performed at Intermediate In-Course Evaluation, but Only by PET Assessed at the End of Therapy.. *Blood*, **2010**, 116, 2819-2819	2.2	3
106	SNP6 Array Better Defines Chronic Lymphocytic Leukemia (CLL) Prognostic Groups. *Blood*, **2010**, 116, 3611-3611	2.2	1

105	13q14 Chromosome Deletion Size and Number of Deleted Cells Influence Prognosis In Chronic Lymphocytic Leukemia. *Blood*, **2010**, 116, 3578-3578	2.2	
104	Retrospective Analysis of 206 Mantle Cell Lymphoma Patients at Diagnosis: Mantle Cell International Prognostic Index (MIPI) Is a Good Predictor of Death Event In Patients Treated Either with Rituximab-Chemotherapy or Rituximab-High-Dose-Chemotherapy. *Blood*, **2010**, 116, 1784-1784	2.2	1
103	Identification by Serological Proteome Analysis (SERPA) of Tumor-Associated Antigens Eliciting Antibody Responses In Chronic Lymphocytic Leukemia (CLL). *Blood*, **2010**, 116, 917-917	2.2	
102	The Genotype of MLH1 Is An Independent Predictor of Outcome In Diffuse Large B-Cell Lymphoma Treated with R-CHOP: a Training-Validation Study. *Blood*, **2010**, 116, 992-992	2.2	
101	High Expression of mRNA and Gene Amplification of Met In Myeloma Plasma Cells Characterize a More Aggressive Disease. *Blood*, **2010**, 116, 1898-1898	2.2	
100	The Defective Proliferation of Vgamma9Vdelta2 T Cells to Zoledronic Acid In Chronic Lymphocytic Leukemia (CLL) Is a Powerful Time to First Treatment (TFT) Predictor Associated with the IGHV Mutational Status. *Blood*, **2010**, 116, 3602-3602	2.2	
99	IGH Repertoire Analysis In Multiple Myeloma (MM): Lack of Intra-Disease Homology and Occasional Clustering with Sequences of Other B-Cell Neoplasms Sharing Identical Geographical Origin. *Blood*, **2010**, 116, 2951-2951	2.2	
98	IGHV Unmutated Chronic Lymphocytic Leukemia (CLL) B Cells Are More Susceptible to Spontaneous Apoptosis Than Mutated CLL B Cells and Are Subject to the Anti-Apoptotic Effect of Environmental Signals. *Blood*, **2010**, 116, 2431-2431	2.2	
97	Prospective, Multicenter Phase II Pilot Trial to Evaluate Efficacy and Safety of Lenalidomide Plus Rituximab-CHOP21 (LR-CHOP21) for Elderly Patients with Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Interim Analysis of the Intergruppo Italiano Linfomi (IIL) REAL07 Study. *Blood*, **2010**, 116, 2871-2871	2.2	
96	Severe Telomeric Erosion In Ph-Negative Hematopoiesis After Successful CML Treatment: Association with Acquired Cytogenetic Lesions and Hematological Toxicity.. *Blood*, **2010**, 116, 3375-3375	2.2	
95	Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndrome. *Clinical Cancer Research*, **2009**, 15, 4415-22	12.9	155
94	Telomere length is an independent predictor of survival, treatment requirement and Richter's syndrome transformation in chronic lymphocytic leukemia. *Leukemia*, **2009**, 23, 1062-72	10.7	85
93	Rituximab (R) Maintenance Versus Observation After Short Term Chemoimmunotherapy R-FND as First Line Treatment in Elderly Patients with Advanced Follicular Lymphoma (FL): Updated Results and Safety of the Maintenance of An Intergruppo Italiano Linfomi (IIL) Randomized Trial.. *Blood*, **2009**, 114, 1796-1796	2.2	1
92	A Recent Update of Three Consecutive Prospective Trials with High-Dose Therapy and Autograft, without or with Rituximab, as Primary Treatment for Advanced-Stage Follicular Lymphoma (FL) Shows a Sizeable Group of Patients Surviving in Continuous Complete Remission up to 16 Years After the End of Treatment: Should We Still Consider FL An Incurable Disease?.. *Blood*, **2009**, 114, 882-882	2.2	1
91	Correlation Between Clinical Outcome and Disease Kinetics by Quantitative PCR in Myeloma Patients Following Post-Transplant Consolidation with Bortezomib, Thalidomide and Dexamethasone.. *Blood*, **2009**, 114, 960-960	2.2	2
90	Interim 18-FDG-Positron Emission Tomography/Computed Tomography (PET) Failed to Predict Different Outcome in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Treated with Rituximab-CHOP.. *Blood*, **2009**, 114, 99-99	2.2	7
89	Mantle Cell International Prognostic Index (MIPI) Is a Strong Predictor of the Outcome of Mantle Cell Lymphoma (MCL) in the Rituximab (R) Era.. *Blood*, **2009**, 114, 2928-2928	2.2	
88	Differential Effects of Microenvironmental Elements On Tumor Cells Survival in Chronic Lymphocytic Leukemia Patient Subsets with Good or Poor Prognosis.. *Blood*, **2009**, 114, 2333-2333	2.2	

87	Met Over-Expression Is a Prognostic Factor for Myeloma Patients Treated with Novel Agents.. *Blood*, **2009**, 114, 1821-1821	2.2	
86	Ph-Negative Hematopoiesis Emerging After Successful Treatment of Chronic Myeloid Leukemia Displays Severe and Persistent Telomeric Loss Which Is Particularly Prominent in Patients with Acquired Cytogenetic Abnormalities.. *Blood*, **2009**, 114, 2164-2164	2.2	
85	Characteristics of the Immunoglobulin Heavy Chain (IgH) Rearrangement in Multiple Myeloma (MM): An Analysis On 308 Cases.. *Blood*, **2009**, 114, 2808-2808	2.2	
84	High Response Rate with Favorable Survival Projections in High-Risk Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Receiving R-CHOP-14 or Early Intensified Chemotherapy with Rituximab and Autograft (R-HDS): Results of the Interim Analysis of A GITIL Prospective Multicenter Phase III Study.. *Blood*, **2009**, 114, 1220-1220	2.2	
83	High Resolution Array-CGH Provides New Insights Into the Prognosis of Chronic Lymphocytic Leukemia (CLL): Is 8p Loss Worse Than 17p Loss?.. *Blood*, **2009**, 114, 2339-2339	2.2	
82	Identification of New Recurrent Multiple Small Interstitial Deletions Affecting Genes Coding for Kinases in Chronic Lymphocytic Leukemia (CLL): a New Pathogenic Mechanism?.. *Blood*, **2009**, 114, 672-672	2.2	
81	MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 12885-90	11.5	467
80	CD49d expression is an independent risk factor of progressive disease in early stage chronic lymphocytic leukemia. *Haematologica*, **2008**, 93, 1575-9	6.6	66
79	Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. *Blood*, **2008**, 111, 4004-13	2.2	200
78	AT7519, a Novel Small Molecule Multi-Cyclin Dependent Kinase Inhibitor, Induces Apoptosis in Multiple Myeloma VIA GSK3. *Blood*, **2008**, 112, 251-251	2.2	4
77	Major Shrinking of Residual Tumor Cell Burden and Achievement of Molecular Remissions in Myeloma Patients Undergoing Post-Trasplant Consolidation with Bortezomib, Thalidomide and Dexamethasone: A Qualitative and Quantitative PCR Study. *Blood*, **2008**, 112, 3683-3683	2.2	10
76	Brief Chemoimmunotherapy Rituximab (R)-FND - R Maintenance as First Line Treatment in Elderly Patients with Advanced Follicular Lymphoma (FL): Preliminary Analysis of a Prospective Randomized IIL Trial. *Blood*, **2008**, 112, 834-834	2.2	1
75	Telomere Length Is An Independent Predictor of Survival, Treatment Requirement and Richter's Syndrome Transformation in Chronic Lymphocytic Leukemia.. *Blood*, **2008**, 112, 1052-1052	2.2	
74	Hospital at Home Treatment of Haematological Patients. *Blood*, **2008**, 112, 4686-4686	2.2	
73	Usage of IGHV4-39 with Stereotypic B Cell Receptor Is An Independent Risk Factor of Chronic Lymphocytic Leukemia Transformation to Richter Syndrome. *Blood*, **2008**, 112, 778-778	2.2	
72	Persistent Telomeric Loss and Functional Impairment of Ph-Negative Hematopoiesis after Successful Treatment of Chronic Myelogenous Leukemia. *Blood*, **2008**, 112, 3183-3183	2.2	
71	Telomere length identifies two different prognostic subgroups among VH-unmutated B-cell chronic lymphocytic leukemia patients. *Leukemia*, **2007**, 21, 697-705	10.7	40
70	Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi). *Leukemia*, **2007**, 21, 1802-11	10.7	55

69	Long-term lymphoma survivors following high-dose chemotherapy and autograft: evidence of permanent telomere shortening in myeloid cells, associated with marked reduction of bone marrow hematopoietic stem cell reservoir. *Experimental Hematology*, **2007**, 35, 673-81	3.1	25
68	The new tumor-suppressor gene inhibitor of growth family member 4 (ING4) regulates the production of proangiogenic molecules by myeloma cells and suppresses hypoxia-inducible factor-1 alpha (HIF-1alpha) activity: involvement in myeloma-induced angiogenesis. *Blood*, **2007**, 110, 4464-75	2.2	104
67	MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts. *Blood*, **2007**, 110, 3744-52	2.2	132
66	Front-Line Brief Chemo-Immunotherapy Rituximab (R)-FND + Rituximab Consolidation → Rituximab Maintenance in Elderly Patients with Untreated Advanced Stage Follicular Lymphoma (FL): First Interim Analysis of a Prospective Randomized Study (ML17638). *Blood*, **2007**, 110, 1278-1278	2.2	1
65	The Degree of Telomere Loss in Hematopoietic Cells Correlates with the Risk of Secondary Myelodysplasia/Acute Leukemia Development Following Autologous Stem Cell Transplantation.. *Blood*, **2007**, 110, 1672-1672	2.2	1
64	Long-Term Follow-Up of the Randomized GITMO/IIL Trial Comparing CHOP-Rituximab vs. High-Dose Therapy with Rituximab (R-HDS) in High Risk Follicular Lymphoma (Fl): Updated Results Suggest the Use of R-HDS as Salvage Treatment.. *Blood*, **2007**, 110, 20-20	2.2	1
63	Consolidation with Bortezomib, Thalidomide and Dexamethasone Induces Molecular Remissions in Autografted Multiple Myeloma Patients.. *Blood*, **2007**, 110, 530-530	2.2	8
62	Telomere Length of Hematopoietic Cells Following Autologous and Allogeneic Stem Cell Transplant (SCT) Reflects That of Grafted Cells: Can the Transplant of Younger Stem Cells Be Exploited To Rejuvenate Hematopoiesis?.. *Blood*, **2007**, 110, 3025-3025	2.2	
61	Non-Hodgkin's Lymphoma Refractory to First Line Therapy: Incidence, Associated Clinical and Histological Factors, and Outcome among 503 Newly Diagnosed Patients.. *Blood*, **2007**, 110, 1373-1373	2.2	
60	Phenotypic and Functional Features of Vδ1/Vδ2 T Cells in Chronic Lymphocytic Leukemia Are Strongly Correlated with the Mutational Status of the Immunoglobulin Heavy Chain Variable Region (IgVH) and Metabolic Activity of the Mevalonate Pathway in Tumor Cells.. *Blood*, **2007**, 110, 1131-1131	2.2	
59	Cells carrying nonlymphoma-associated bcl-2/IgH rearrangements (NLABR) are phenotypically related to follicular lymphoma and can establish as long-term persisting clonal populations. *Experimental Hematology*, **2006**, 34, 1680-6	3.1	11
58	Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma. *Biology of Blood and Marrow Transplantation*, **2006**, 12, 1270-6	4.7	47
57	Prolonged survival and low incidence of late toxic sequelae in advanced follicular lymphoma treated with a TBI-free autografting program: updated results of the multicenter consecutive GITMO trial. *Leukemia*, **2006**, 20, 1840-7	10.7	17
56	High-risk fludarabine-pretreated B-cell chronic lymphocytic leukemia's high response rate following sequential DHAP and alemtuzumab administration though in absence of molecular remission. *Medical Oncology*, **2006**, 23, 359-68	3.7	4
55	Clinical and Molecular Results of the Multicenter Randomized GITMO-IIL Trial in Poor Risk Follicular Lymphoma (FL) at Diagnosis: Rituximab-Supplemented High-Dose Sequential Chemotherapy (R-HDS) Is Superior to CHOP-R in Molecular Remissions Rate, EFS and PFS.. *Blood*, **2006**, 108, 325-325	2.2	2
54	MLN3897, a Novel CCR1 Antagonist, Inhibits Osteoclastogenesis by Blocking Early ERK Activation.. *Blood*, **2006**, 108, 1636-1636	2.2	
53	Impact of Early Consolidation with Bortezomib, Thalidomide and Dexamethasone on Molecularly-Detectable Disease in MM Patients in CR or VGPR Following Autologous Transplantation: Uncommon Achievement of Molecular Remission Despite Evidence of Tumor Load Reduction by Real Time PCR.. *Blood*, **2006**, 108, 3100-3100	2.2	
52	p29ING4 Regulates the Production of Pro-Angiogenic Molecules by Human Myeloma Cells in Normoxic and Hypoxic Conditions Being Involved in Myeloma-Induced Angiogenesis.. *Blood*, **2006**, 108, 515-515	2.2	1

51	Suspension of Vitamin K Antagonists Is Not Required for Cataract Surgery: A Prospective Study in a Cohort of 135 Consecutive Patients on Long-Term Anticoagulant Therapy.. *Blood*, **2006**, 108, 882-882	2.2	
50	Immunoglobulin (Ig) Repertoire in Multiple Myeloma: High Frequency of Recurrent Aminoacid Substitutions in the FR2 and CDR2.. *Blood*, **2006**, 108, 3413-3413	2.2	
49	Cyclooxygenase-2 (COX-2) is frequently expressed in multiple myeloma and is an independent predictor of poor outcome. *Blood*, **2005**, 105, 4784-91	2.2	74
48	Marked telomere shortening in mobilized peripheral blood progenitor cells (PBPC) following two tightly spaced high-dose chemotherapy courses with G-CSF. *Leukemia*, **2005**, 19, 644-51	10.7	26
47	Real-time polymerase chain reaction of immunoglobulin rearrangements for quantitative evaluation of minimal residual disease in myeloma. *Methods in Molecular Medicine*, **2005**, 113, 145-63		7
46	High CR Rate and Prolonged EFS in aaIPI 2 B Diffuse Large B-Cell Lymphoma Following High-Dose Sequential Chemotherapy and In Vivo Rituximab-Purged Stem Cell Autografting (R-HDS Regimen): Results of a Prospective Phase II Multicenter Study Sponsored by GITIL (Gruppo Italiano Terapie	2.2	1
45	Rituximab-Supplemented High-Dose Sequential Chemotherapy (HDS) Has Superior Response Rate and Event-Free Survival (EFS) Compared to R-CHOP in Poor Risk Follicular Lymphoma (FL) at Diagnosis: Results from a Multicenter Randomized GITMO Trial.. *Blood*, **2005**, 106, 675-675	2.2	3
44	High Prevalence of Hyperhomocysteine in Retinal Vein Occlusion.. *Blood*, **2005**, 106, 1617-1617	2.2	
43	Telomere Length Identifies Two Distinct Populations with Different Outcome among VH-Unmutated CLL Patients.. *Blood*, **2005**, 106, 2104-2104	2.2	
42	Array-Based Comparative Genomic Hybridization (Array-CGH) in Multiple Myeloma (MM) and Plasma Cell Leukemia (PCL): Recurrent Imbalances within a Highly Heterogeneous Background of Genomic Disruption.. *Blood*, **2005**, 106, 5088-5088	2.2	
41	Long-term follow-up of indolent lymphoma patients treated with high-dose sequential chemotherapy and autografting: evidence that durable molecular and clinical remission frequently can be attained only in follicular subtypes. *Journal of Clinical Oncology*, **2004**, 22, 1460-8	2.2	113
40	Telomere length correlates with histopathogenesis according to the germinal center in mature B-cell lymphoproliferative disorders. *Blood*, **2004**, 103, 4644-9	2.2	39
39	Sequential Brief Chemo-Immunotherapy FND + Rituximab in Elderly Patients with Advanced Stage Follicular Lymphoma (FL): High Clinical and Molecular Remission Rate Associated with a Prolonged Failure-Free Survival.. *Blood*, **2004**, 104, 1320-1320	2.2	2
38	Telomerase Inhibitor BIBR1532 Induces Telomere Shortening and Growth Inhibition in Extra-Germinal Center (GC)-Derived Lymphoid Cell Lines.. *Blood*, **2004**, 104, 3389-3389	2.2	1
37	Qualitative and Quantitative Molecular Follow up of Minimal Residual Disease after Non Myeloablative Allografting for Multiple Myeloma.. *Blood*, **2004**, 104, 5128-5128	2.2	1
36	Rituximab-Supplemented High-Dose Sequential (HDS) Chemotherapy with Autograft Is Highly Effective in High-Risk (aaIPI 2B) Diffuse Large B-Cell Lymphoma: Results of a Prospective Multicenter Study on 91 Consecutive Patients Treated at Diagnosis.. *Blood*, **2004**, 104, 891-891	2.2	3
35	Cyclooxygenase-2 (COX-2) Is Frequently Expressed in Multiple Myeloma (MM) and Is Associated with Poor Outcome.. *Blood*, **2004**, 104, 2450-2450	2.2	
34	Long-Term Outcome of High-Dose Sequential Chemotherapy with Autografting (i-HDS) in Follicular Lymphoma at Diagnosis: An Update of the Prospective Multicenter Consecutive Trial of the "Gruppo Italiano Trapianto Di Midollo Osseo" (Gitmo).. *Blood*, **2004**, 104, 903-903	2.2	

33	Telomere Length of Hematopoietic Cells in Long-Term Post-Autograft Survivors: No Evidence of Accelerated Replicative Cell Senescence Despite the Persistent Reduction of Both Committed and Immature Progenitor Cell Compartments.. *Blood*, **2004**, 104, 4123-4123	2.2	
32	Long-Term Monitoring of Cancer-Free Subjects Carrying Non-Lymphoma Associated bcl2/IgH Rearrangements (NLABR): Prolonged Persistence of Clonal Populations Potentially Related to Follicular Lymphoma (FL).. *Blood*, **2004**, 104, 1373-1373	2.2	
31	Telomere Length Has Prognostic Impact in B-Cell Chronic Lymphocytic Leukemia (B-CLL).. *Blood*, **2004**, 104, 4768-4768	2.2	
30	Incidence and Risk-Factors of Secondary Myelodysplastic Syndrome/Acute Leukemia Following High-Dose Chemotherapy and Autograft: A Long-Term Analysis on 307 Lymphoma Patients.. *Blood*, **2004**, 104, 2248-2248	2.2	
29	PCR-detectable nonneoplastic Bcl-2/IgH rearrangements are common in normal subjects and cancer patients at diagnosis but rare in subjects treated with chemotherapy. *Journal of Clinical Oncology*, **2003**, 21, 1398-403	2.2	33
28	Recurrence of Bcl-2/IgH polymerase chain reaction positivity following a prolonged molecular remission can be unrelated to the original follicular lymphoma clone. *Experimental Hematology*, **2003**, 31, 784-8	3.1	12
27	Patients with high-risk aggressive lymphoma treated with frontline intensive chemotherapy and autografting: evidence of marked differences in outcome between patients with age-adjusted International Prognostic Index scores 2 and 3. *Cancer*, **2003**, 98, 983-92	6.4	14
26	Detection of minimal residual disease by real-time PCR can be used as a surrogate marker to evaluate the graft-versus-myeloma effect after allogeneic stem cell transplantation. *Bone Marrow Transplantation*, **2003**, 32, 791-3	4.4	7
25	BRAF gene is not mutated in plasma cell leukemia and multiple myeloma. *Leukemia*, **2003**, 17, 2238-40	10.7	15
24	Real-time polymerase chain reaction in multiple myeloma: quantitative analysis of tumor contamination of stem cell harvests. *Experimental Hematology*, **2002**, 30, 529-36	3.1	22
23	Qualitative and quantitative polymerase chain reaction detection of the residual myeloma cell contamination after positive selection of CD34+ cells with small- and large-scale Miltenyi cell sorting system. *British Journal of Haematology*, **2002**, 117, 642-5	4.5	9
22	Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies. *Blood*, **2002**, 99, 75-82	2.2	133
21	High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO). *Blood*, **2002**, 100, 1559-65	2.2	80
20	Cytomegalovirus infection in cancer patients receiving granulocyte transfusions. *Blood*, **2002**, 99, 390-1	2.2	10
19	High-dose mitoxantrone + melphalan (MITO/L-PAM) as conditioning regimen supported by peripheral blood progenitor cell (PBPC) autograft in 113 lymphoma patients: high tolerability with reversible cardiotoxicity. *Leukemia*, **2001**, 15, 256-63	10.7	23
18	Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphoma. *Leukemia*, **2001**, 15, 1941-9	10.7	42
17	A validated real-time quantitative PCR approach shows a correlation between tumor burden and successful ex vivo purging in follicular lymphoma patients. *Experimental Hematology*, **2001**, 29, 183-93	3.1	57
16	Central nervous system relapse in a patient with mantle cell lymphoma in continuous clinical and molecular remission at six years since autografting. *Leukemia and Lymphoma*, **2001**, 40, 679-82	1.9	6

15	Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell malignancies. *Nature Medicine*, **2000**, 6, 667-72	50.5	155
14	Long-term follow-up of advanced-stage low-grade lymphoma patients treated upfront with high-dose sequential chemotherapy and autograft. *Leukemia*, **2000**, 14, 740-7	10.7	31
13	Rituximab anti-CD20 monoclonal antibody induces marked but transient reductions of peripheral blood lymphocytes in chronic lymphocytic leukaemia patients. *Medical Oncology*, **2000**, 17, 203-10	3.7	25
12	Immunoglobulin heavy-chain consensus probes for real-time PCR quantification of residual disease in acute lymphoblastic leukemia. *Blood*, **2000**, 95, 2651-2658	2.2	120
11	Real-Time polymerase chain reaction of immunoglobulin rearrangements for quantitative evaluation of minimal residual disease in multiple myeloma. *Biology of Blood and Marrow Transplantation*, **2000**, 6, 241-53	4.7	76
10	Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells. *Journal of Clinical Oncology*, **1999**, 17, 208-15	2.2	198
9	Negative immunomagnetic ex vivo purging combined with high-dose chemotherapy with peripheral blood progenitor cell autograft in follicular lymphoma patients: evidence for long-term clinical and molecular remissions. *Leukemia*, **1999**, 13, 1456-62	10.7	35
8	Clinical relevance of minimal residual disease monitoring in non-Hodgkin's lymphomas: a critical reappraisal of molecular strategies. *Leukemia*, **1999**, 13, 1691-5	10.7	37
7	Molecular Monitoring of Minimal Residual Disease in Follicular and Mantle Cell Non-Hodgkin's Lymphomas Treated With High-Dose Chemotherapy and Peripheral Blood Progenitor Cell Autografting. *Blood*, **1997**, 89, 724-491	2.2	142
6	A novel nested-PCR strategy for the detection of rearranged immunoglobulin heavy-chain genes in B cell tumors. *Leukemia*, **1997**, 11, 1793-8	10.7	94
5	Analysis of the immunoglobulin heavy-chain gene rearrangement providing molecular evidence of second lymphoma in a patient in apparent relapse after autotransplantation. *Bone Marrow Transplantation*, **1997**, 20, 341-3	4.4	5
4	Clinical and molecular remission after allogeneic blood cell transplantation in a patient with mantle-cell lymphoma. *British Journal of Haematology*, **1996**, 94, 376-8	4.5	26
3	Oncogenes in the Pathogenesis of Multiple Myeloma **1996**, 169-172		
2	N- and K-ras oncogenes in plasma cell dyscrasias. *Leukemia and Lymphoma*, **1994**, 15, 17-20	1.9	23
1	The mutation of N-ras oncogene does not involve myeloid and erythroid lineages in a case of multiple myeloma. *British Journal of Haematology*, **1993**, 83, 672-3	4.5	3